<?xml version="1.0" encoding="UTF-8"?>
<p id="p0035">The documents were then classified by zone, country, regulatory authority, information format, and topic area. These documents were also further classified into what we refer to as “regulatory agilities” by flagging those that explicitly indicate, within the text, the use of exceptional measures or flexible approaches of a regulation or regulatory process, which ultimately aim to facilitate the review, approval, and availability of medical products during the COVID-19 pandemic within the January to July 2020 time frame. We have then used these data as a basis for extracting trends, learnings, and potential ways forward. To put trends and learnings into perspective, additional information was gathered through a literature review and analysis of related data available from the public domain, as were the authors' experiences within the company.</p>
